

Legislative Counsel Brenda Erdoes and I met with Senator Cancela and representatives of the pharmaceutical industry concerning the issues presented by sections 7, 8, and 27.5 of Senate Bill 265. We found that most of the problems that the industry representatives mentioned in the meeting were policy concerns related to the difficulty of complying with the requirements of the bill and the potential effects of enacting the bill. These concerns would not result in the bill being struck down in court. To the extent that the concerns expressed by the industry representatives were legal in nature, this office had previously researched those concerns and has determined that all provisions of Senate Bill 265 are legally defensible.

Sincerely,

Eric Robbins

Principal Deputy Legislative Counsel

Legal Division

Nevada Legislative Counsel Bureau